TVTX
NASDAQ · Biotechnology
Travere Therapeutics Inc
$48.97
-3.45 (-6.58%)
Financial Highlights (FY 2026)
Revenue
513.86M
Net Income
-26,754,790
Gross Margin
97.9%
Profit Margin
-5.2%
Rev Growth
+32.3%
D/E Ratio
2.71
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 97.9% | 97.9% | 53.7% | 53.7% |
| Operating Margin | -12.8% | -11.5% | 9.4% | 7.8% |
| Profit Margin | -5.2% | -5.0% | 9.6% | 8.5% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 513.86M | 388.47M | 873.79M | 704.19M |
| Gross Profit | 503.02M | 380.27M | 469.44M | 378.33M |
| Operating Income | -65,774,334 | -44,751,210 | 81.83M | 54.90M |
| Net Income | -26,754,790 | -18,203,289 | 83.63M | 59.82M |
| Gross Margin | 97.9% | 97.9% | 53.7% | 53.7% |
| Operating Margin | -12.8% | -11.5% | 9.4% | 7.8% |
| Profit Margin | -5.2% | -5.0% | 9.6% | 8.5% |
| Rev Growth | +32.3% | +32.3% | +12.5% | -3.6% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 1.74B | 1.74B | 191.77M | 223.22M |
| Total Equity | 639.33M | 639.33M | 1.35B | 1.30B |
| D/E Ratio | 2.71 | 2.71 | 0.14 | 0.17 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -3,783,411 | -2,717,145 | 111.75M | 89.10M |
| Free Cash Flow | — | — | 68.75M | 73.37M |